West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc.

WSTNYSE / NASDAQHealthcareLarge cap

$390.30-$6.39 (-1.6%)

Last close · Data as of Nov 20, 2026

Market cap
$22.4B
P/E
45.4x
EV / EBITDA
28.4x
Revenue
$3.1B
Net margin
16.1%
ROCE
17.6%

+51.4% over the last year

West Pharmaceutical Services, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+0.4%
3M
+10.3%
6M
+27.8%
1Y
+51.4%
5Y
-13.0%

52-week range

Day change -$6.39 (-1.6%) from $397 to $390 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in WST, bought on each weekday since 2021.

News & filings

What West Pharmaceutical Services filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating profit was more than a hundred times interest costs.

Concerns (1)

  • The P/E of 45.4 is 107% above the peer median of 21.9.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

Read moreShow less

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

Sector
Healthcare
Shares outstanding
72.3M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$22.4B
P/E
45.4x
P/B
7.1x
EV / EBITDA
28.4x
EV / Sales
7.1x
P/S
7.3x
52-week high
$417.80
52-week low
$230.95

Profitability

Operating margin
20.7%
Net margin
16.1%
EBITDA margin
25.1%
ROE
15.5%
ROCE
17.6%
ROA
11.6%
Asset turnover
0.72

Growth

Revenue
$3.1B
Revenue growth, 1Y
6.3%
Revenue CAGR, 3Y
2.1%
Net profit growth, 1Y
0.2%
Free cash flow
$468.9M

Solvency

Current ratio
3.02
Debt / Equity
0.10
Debt / Assets
0.08
CFO / Net profit
1.53
Cash / Market cap
3.5%

Where the revenue went

Of every $100 of FY2025 revenue, $16 was left as net income.

West Pharmaceutical Services, Inc. income statement flow, FY2025
West Pharmaceutical Services, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$2.0B
RevenueGross profit$1.1B
Gross profitOperating expenses$467.9M
Gross profitOperating income$636.1M
Operating incomePretax income$600.9M
Operating incomeInterest and other expense$35.2M
Pretax incomeTax and other$107.2M
Pretax incomeNet income$493.7M

Revenue and net profit

Revenue grew 6.3% in FY2025; net profit is the dashed line.

West Pharmaceutical Services, Inc. revenue and net profit by fiscal year
West Pharmaceutical Services, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$2.9B$585.9M
FY2023$2.9B$593.4M
FY2024$2.9B$492.7M
FY2025$3.1B$493.7M

Cash flows

FY2025: $754.8M from operations, $468.9M free after investment (dashed).

West Pharmaceutical Services, Inc. operating and free cash flow by fiscal year
West Pharmaceutical Services, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$724.0M$439.4M
FY2023$776.5M$414.5M
FY2024$653.4M$276.4M
FY2025$754.8M$468.9M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$3.1B+6.3%1Y
EBITDA
$772.8M+3.9%1Y
Net profit
$493.7M+0.2%1Y
Cash from operations
$754.8M+15.5%1Y
Free cash flow
$468.9M+69.6%1Y
Revenue CAGR, 3Y
2.1%
Net profit CAGR, 3Y
-5.5%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$3.1B$772.8M$493.7M$468.9M15.5%+6.3%+0.2%

Monthly returns

Month-by-month returns of WST across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$4.3B
Liabilities$1.1B
Equity$3.2B
Paid-in capital$0.00
Retained earnings$4.4B
Treasury stock$1.1B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; WST highlighted.

P/E against peers

WST trades at 45.4x earnings against a peer median of 21.9x (a 107% premium).

  1. West Pharmaceutical Services, Inc. (this company)45.4x

Not shown (no positive earnings and no EV / Sales): Insmed Incorporated, Moderna, Inc., Viatris Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
West Pharmaceutical Services, Inc.WSTthis companyP/E ↑ premium$22.4B45.4x7.1x15.5%28.4x
Mettler-Toledo International Inc.MTD$23.9B27.4x—-3676.8%20.9x
Insmed IncorporatedINSM$22.7B-17.8x30.8x-172.8%—
Quest Diagnostics IncorporatedDGX$21.7B21.9x3.0x13.8%12.9x
Labcorp Holdings Inc.LH$21.4B24.4x2.5x10.2%13.6x
STERIS plcSTE$20.7B26.5x2.9x10.9%14.0x
Moderna, Inc.MRNA$20.5B-7.3x2.4x-32.6%-7.5x
Incyte CorporationINCY$20.2B15.7x3.9x24.9%9.8x
Viatris Inc.VTRS$18.5B—1.3x-23.9%—
Peer median—21.9x2.9x-6.9%13.2x

Year-to-date ROI

WST since 1 January, against earlier years.

Historical volatility

WST's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

West Pharmaceutical Services, Inc. operating margin by fiscal year
West Pharmaceutical Services, Inc. operating margin by fiscal year
DateOperating margin
FY202226.4%
FY202324.0%
FY202420.4%
FY202520.7%
LineFY2025
Cost of revenueCost Of Revenue$2.0B
Gross profitGross Profit$1.1B
Operating expensesOperating Expense$467.9M
Research and developmentResearch And Development$74.3M
Selling, general and administrativeSelling General And Administration$393.6M
Total expensesTotal Expenses$2.4B
Pretax incomePretax Income$600.9M

Learn while you research

Academy chapters picked for West Pharmaceutical Services, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 45.4, learn when high multiples are justified.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →